Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-up of the Phase 3 ILLUMINATE-C Trial. - Sellier-Leclerc AL; Magen D; Shasha-Lavsky H; Simkova E; Devresse A; Guebre-Egziabher F; Michael M; Lieske JC; Frishberg Y; Bakkaloglu SA; Mourani C; Saqan R; et al. (American journal of kidney diseases : the official journal of the National Kidney Foundation, 2025)